Total Wealth Planning & Management Inc. Makes New $593,000 Investment in Hims & Hers Health, Inc. $HIMS

Key Points

• Total Wealth Planning & Management Inc. invested approximately $593,000 in Hims & Hers Health, acquiring 11,904 shares in the second quarter.
• Insider trading at Hims & Hers recently featured significant sales, including CEO Andrew Dudum selling 660,000 shares for about $33.4 million, representing a 22.96% decrease in ownership.
• Hims & Hers Health reported a missed earnings estimate in its recent quarterly results, posting $0.17 earnings per share compared to the expected $0.18.

Total Wealth Planning & Management Inc. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,904 shares of the company's stock, valued at approximately $593,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after buying an additional 227 shares in the last quarter. True Vision MN LLC raised its stake in Hims & Hers Health by 3.6% in the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after buying an additional 328 shares in the last quarter. Allworth Financial LP raised its stake in Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after buying an additional 334 shares in the last quarter. Signaturefd LLC raised its stake in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after buying an additional 388 shares in the last quarter. Finally, Kilter Group LLC raised its stake in Hims & Hers Health by 1.0% in the first quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after buying an additional 450 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares of the company's stock, valued at $9,105,385.20. This trade represents a 26.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,622,741 shares of company stock valued at $83,695,469. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Down 0.1%

HIMS opened at $58.13 on Friday. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 1-year low of $17.36 and a 1-year high of $72.98. The company has a market capitalization of $13.14 billion, a PE ratio of 72.67, a PEG ratio of 3.93 and a beta of 2.25. The firm's 50 day simple moving average is $51.03 and its two-hundred day simple moving average is $47.78.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm's revenue was up 72.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on HIMS. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Truist Financial cut their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Hims & Hers Health presently has an average rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.